Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Pilot Efficacy Study and Exploratory Evaluation of the Systemic Bioavailability of Single and/or Multiple Doses of RECCE327 Topical Gel Applied to Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Next Previous
Trial Profile

An Open-label, Pilot Efficacy Study and Exploratory Evaluation of the Systemic Bioavailability of Single and/or Multiple Doses of RECCE327 Topical Gel Applied to Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RECCE 327 (Primary)
  • Indications Bacterial infections; Skin infections
  • Focus Therapeutic Use
  • Sponsors Recce Pharmaceuticals

Most Recent Events

  • 10 Apr 2025 According to a Recce Pharmaceuticals media release, According to a Recce Pharmaceuticals media release, the company has procured a capital raising of up to approximately A$15.8 million, which will be used to fund this study, and support the achievement of all its end-points.
  • 19 Feb 2025 Results (n=29) presented in the Recce Pharmaceuticals Media Release.
  • 17 Feb 2025 According to a Recce Pharmaceuticals media release, data from this trial aligned with the US Food and Drug Administration (FDA) increased demand for novel broad-spectrum antibiotics (such as R327G) to address antimicrobial resistance. Data confirms approach for registrational phase 3 diabetic foot infections Indonesian trial

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top